Hyperuricemia, Liver Fibrosis, NAFLD (Nonalcoholic Fatty Liver Disease)
Conditions
Brief summary
1. Identifying the association between hyperuricemia and NAFLD can lead to early detection and prevention of liver fibrosis in adult obese patients. 2. Understanding the relationship between hyperuricemia and NAFLD can inform targeted therapy, such as urate-lowering treatment, to potentially slow disease progression. 3 - To examine the relationship between serum uric acid levels and liver fibrosis severity\*: Assessing the correlation between serum uric acid levels and the severity of liver fibrosis in adult obese patients with NAFLD. 4- To identify potential mechanisms underlying the association\*: Exploring the potential mechanisms by which hyperuricemia may contribute to the development and progression of NAFLD and liver fibrosis in adult obese patients.
Detailed description
Hyperuricemia is associated with nonalcoholic fatty liver disease (NAFLD), whereas whether the association differed by hyperuricemia onset age remained unclear. This study sought to investigate the associations of hyperuricemia onset age with the risk of incident NAFLD across adulthood. Obesity has been demonstrated to show a consistent link with the increased possibility of nonalcoholic fatty liver disease (NAFLD). Since both serum uric acid (SUA) and obesity are essential components of metabolic syndrome (MetS), it is uncertain whether the incidence of NAFLD results from serum uric acid, obesity, or other potential factors based on previous studies.
Interventions
Lab methods
Imaging
Instrument
Sponsors
Study design
Eligibility
Inclusion criteria
1. Age: Adults (typically 18-65 years old) 2 - Body Mass Index (BMI): Obese patients with a BMI ≥ 30 kg/m² 3- Hyperuricemia : Elevated serum uric acid levels (typically \> 7 mg/dL for men and \> 6 mg/dL for women)
Exclusion criteria
* excessive alcohol consumption ( \> 20 gm /day in men and 10 in g /day in women ) 2- use of steatogenic within the past 6 months 3- positive test for hepatitis B surface antigen and hepatitis B core antibody 4- Drug induced liver injury and autoimmune hepatitis 5 - cirrhosis and other causes of liver disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of NAFLD | 1 year | The proportion of adult obese patients with NAFLD in the study population |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum uric acid level | 1 year | The serum uric acid level in adult obese patients |